Blogs & News

Pharm to Farm: Learn about Huvepharma, Inc.’s mission to bring new choices to livestock producers

In the U.S., Huvepharma, Inc. has had a presence since 2005 primarily with animal health, feed additive and enzyme products for the poultry and swine sectors. FDA-approval of Monovet® 90 (Monensin Type A Medicated Article)

In July 2019 marked Huvepharma’s first product available for the U.S. cattle sector. Monovet® 90 (Monensin Type A Medicated Article) is also the first FDA-approved bioequivalent for monensin, which means U.S. producers now have an alternative source for monensin –a product that previously could only be purchased from one company.

Additionally, Huvepharma’s development of RESPIVax™ 5 + PH-M – a 5-way viral, 2- way pasteurella vaccine to protect cattle against viral bacterial challenges associated with Bovine Respiratory Disease (BRD) – gives producers another choice for a 5-way vaccine. Several additional new product approvals – many of them bioequivalents – have followed including Optigrid® 45 (ractopamine hydrochloride), CycleGuard® 500 (Melengestrol Acetate Type A Liquid Medicated Article), and Vetmulin®12.5% (tiamulin hydrogen fumarate), and a suite of additional products are expected since Huvepharma holds 21 of the 50 animal health FDA approvals from 2019.

Adding to Huvepharma’s livestock industry commitment are the team of industry experts they’ve assembled who have hands-on experience with production animals, both in their careers and in their personal lives.

As well, Huvepharma’s sole focus is on production animals, rather than companion animals, to maximize the company’s investment dollars and develop the best possible products with emphasis on nutrition, prevention and treatment options for cattle, poultry and swine.

With that, Huvepharma’s expanding portfolio of feed additives, vaccines and pharmaceutical products is presenting cattle, poultry and swine producers with new choices – in many cases for the first time in a long time. Rick Cozzitorto, head of US sales & marketing, sums up the company’s mission with these words, “The production animal industry has remained virtually untouched for years, giving producers limited options in products and process. Huvepharma brings a new approach that fits the needs of its customers. We are growing in a strategic and thoughtful manner to maintain consistent pricing and ensure the best quality product is always accessible to producers. We are excited about the possibilities.”

Optigrid®45 (ractopamine hydrochloride) is not for animals intended for breeding. The active ingredient in Optigrid®45, ractopamine hydrochloride, is a beta-adrenergic agonist. Individuals with cardiovascular disease should exercise special caution to avoid exposure. Not for use in humans. Keep out of reach of children. The Optigrid 45 formulation (Type A Medicated Article) poses a low dust potential under usual conditions of handling and mixing. When mixing and
handling Optigrid, use protective clothing, impervious gloves, protective eye wear, and a NIOSH-approved dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse eyes thoroughly with water. If irritation persists, seek medical attention. 

CycleGuard® 500 (Melengestrol Acetate Type A Liquid Medicated Article) is not effective in steers and spayed heifers. Heifers Fed in Confinement for Slaughter: Withdrawal periods of three to five days or more should be avoided to prevent the possibility that the heifers may come into estrus (heat) at loading time. Heifers Intended for Breeding: Do not exceed 24 days of feeding of melengestrol acetate to heifers intended for breeding. A reduced conception rate can be expected if heifers are bred at estruses observed within 1 to 12 days after withdrawal of melengestrol acetate, whereas heifers bred at subsequent observed estruses are expected to have normal conception rates. View product label here. Vetmulin® 12.5% (tiamulin hydrogen fumarate) Not For Human Use. Keep out of reach of children. Withdraw medicated water 3 days before slaughter after treatment at 3.5 mg per pound of body weight and 7 days before slaughter after treatment at 10.5 mg per body weight. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined. Swine being treated with Vetmulin should not have access to feeds containing polyether ionophores as adverse reactions may occur. Overdoses have sometimes produced transitory salivation, vomiting and an apparent calming effect on the pig. If signs of toxicity occur, discontinue use. 

Monovet® 90 (Monensin Type A Medicated Article) Not For Human Use. Consumption by unapproved species may result in toxic reactions and even fatalities. A withdrawal time has not been established for pre-ruminating calves. Do not use in calves to be processed for veal. When mixing and handling use protective clothing, impervious gloves and a dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse with water. 

To report adverse effects, access medical information, or obtain additional product information,
call 1-877-426-7765.